Acurx announces scientific oral and poster presented at idweek 2022

Presents research on ibezapolstat's selective activity on healthy bacteria within the gut microbiome in the treatment of c. difficile infection (cdi) emerging ibezapolstat microbiome data demonstrate that favorable effects seen in the ph1 healthy volunteer study are also observed in the ph2a trial in cdi patients treated with ibezapolstat currently enrolling ph2b trial in up to 30 u.s. sites will compare efficacy of ibezapolstat to vancomycin ibezapolstat is fda qidp and fast track designated for priority review staten island, n.y.
ACXP Ratings Summary
ACXP Quant Ranking